R
Russell Esterline
Researcher at AstraZeneca
Publications - 19
Citations - 340
Russell Esterline is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Dapagliflozin. The author has an hindex of 5, co-authored 9 publications receiving 111 citations.
Papers
More filters
Book ChapterDOI
A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
TL;DR: It is hypothesized that sodium glucose cotransporter 2 (SGLT2) inhibition, mediated by sustained glucose loss, restores mTOR cycling through nutrient-driven, nightly periods of transient mTOR inhibition (and restoration of catabolic cellular housekeeping processes) interspersed by daily periods of temporary mTOR activation (and anabolism) accompanying eating, thereby preventing or even reducing the progress of AD pathology.
Journal ArticleDOI
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.
Yvo J.M. Op den Kamp,Marlies de Ligt,Bas Dautzenberg,Esther Kornips,Russell Esterline,Matthijs K. C. Hesselink,Joris Hoeks,Vera B. Schrauwen-Hinderling,Bas Havekes,Jan Oscarsson,Esther Phielix,Patrick Schrauwen +11 more
TL;DR: In this paper, the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes were investigated, and the differences in least squares mean (95% CI) between treatments were compared.
Journal ArticleDOI
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
Elmar Zügner,Hsiu-Chiung Yang,Petra Kotzbeck,Beate Boulgaropoulos,Harald Sourij,Sepideh H. Hagvall,Charles S. Elmore,Russell Esterline,Sven Moosmang,Jan Oscarsson,Thomas R. Pieber,Xiao-Rong Peng,Christoph Magnes +12 more
TL;DR: The results confirmed cana´s inhibition of mitochondrial activity and GU at supra-pharmacological and pharmacological concentrations, whereas the dapa, ertu, and empa did not show effects even atsupra- pharmacological concentrations.
Journal ArticleDOI
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
Hiddo J.L. Heerspink,Remo H.M. Furtado,Otavio Berwanger,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Samvel B. Gasparyan,Fengming Tang,Sheryl L. Windsor,Vicente Ces de Souza-Dantas,Mildren Del Sueldo,Robert Frankel,Ali Javaheri,Rafael Maldonado,Caryn G. Morse,Marco A. Mota-Gomes,Douglas Shemin,Osvaldo Lourenço Silva,Alexandre Pereira Tognon,Marcel Twahirwa,Joan Buenconsejo,Russell Esterline,Jan Oscarsson,Phil Ambery,Anna Maria Langkilde,Mikhail Kosiborod +26 more
TL;DR: In patients hospitalized with COVID-19, treatment with dapagliflozin versus placebo resulted in numerically fewer participants who experienced organ failure or death, although these differences were not statistically significant.
Journal ArticleDOI
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
Samvel B. Gasparyan,Joan Buenconsejo,E. K. Kowalewski,Jan Oscarsson,Olof Bengtsson,Russell Esterline,Gary G. Koch,Otavio Berwanger,Mikhail Kosiborod +8 more
TL;DR: In this paper , a hierarchical composite endpoint (HCE) is proposed to measure the treatment effect of dapagliflozin in hospitalized patients with COVID-19 pneumonia and cardiometabolic risk factors.